Elimination of CD4+CD25+ Regulatory T Cells in Patients With Hepatocellular Carcinoma
NCT ID: NCT00396682
Last Updated: 2009-02-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
12 participants
INTERVENTIONAL
2007-02-28
2008-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma
NCT04634357
CAR-T Cell Immunotherapy for HCC Targeting GPC3
NCT02723942
Adjuvant Therapy With Thalidomide After Curative Resection of Hepatocellular Carcinoma
NCT01924624
TCR-Redirected T Cells Therapy in Patient With HBV Related HCC
NCT03899415
Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant
NCT05027425
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cyclophosphamide
150 - 250 - 350 mg
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* adequate liver and kidney function
* no immunodeficiency
* ECOG \< 2
Exclusion Criteria
* severe cardiopulmonary diseases
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hannover Medical School
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Med. Hochschule Hannover
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tim F Greten, M.D.
Role: PRINCIPAL_INVESTIGATOR
Department of Gastroenterology, Medizinische Hochschule Hannover
Tim F Greten, M.D.
Role: PRINCIPAL_INVESTIGATOR
Hannover Medical School
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medizinische Hochschule Hannover
Hanover, , Germany
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Greten TF, Ormandy LA, Fikuart A, Hochst B, Henschen S, Horning M, Manns MP, Korangy F. Low-dose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-specific CD4+ T-cell responses in patients with advanced HCC. J Immunother. 2010 Feb-Mar;33(2):211-8. doi: 10.1097/CJI.0b013e3181bb499f.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DFG - KFO 119
Identifier Type: -
Identifier Source: secondary_id
HAN-HCC-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.